Processing times for complaints against drug companies suspected of having breached their industry code of practice have more than tripled in a nearly two-decade period, an investigation by The BMJ has found.
Feb 14, 2024
0
0
The biggest quandary in the obesity drug market is that nobody knows just how big it will be. Everyone agrees it'll be huge—currently, Eli Lilly & Co. is worth more than Tesla Inc., and Novo Nordisk A/S is at times the ...
Feb 12, 2024
0
1
Danish pharmaceutical giant Novo Nordisk posted bumper profits for 2023 on Wednesday, driven by blockbuster sales of diabetes and obesity treatments that helped it become Europe's most valuable company.
Jan 31, 2024
0
0
Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet ...
Jan 23, 2024
0
89
State and local governments across the US are grappling with a growing problem: Expensive drugs to treat diabetes and obesity are threatening to drain their health care budgets.
Jan 9, 2024
0
5
Sibling death in childhood and early adulthood is associated with an increased risk for cardiovascular disease (CVD), according to a study published online Jan. 8 in JAMA Network Open.
Jan 8, 2024
0
0
A recent study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat type 2 diabetes and obesity, can lead to a rapid improvement ...
Jan 4, 2024
0
7
The U.S. Food and Drug Administration is investigating reports of additional dangers linked to several wildly popular weight-loss drugs.
Jan 4, 2024
0
18
Managing diabetes will be a less expensive proposition for more Americans in 2024.
Jan 2, 2024
0
9
Brain health after COVID-19 is impaired, but no more than that seen for patients hospitalized for other medical conditions of similar severity, according to a study published online Dec. 28 in JAMA Network Open.
Dec 29, 2023
0
0
